Bubonic Plague (Yersinia pestis)
For the why behind the fact
Use this page to connect what you are memorizing.
Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.
Overview
Plain-Language Overview
Bubonic plague is a serious infectious disease caused by the bacterium Yersinia pestis. It primarily affects the lymphatic system, leading to swollen and painful lymph nodes called buboes. The infection usually starts after a bite from an infected flea, which transmits the bacteria from rodents to humans. Symptoms include sudden fever, chills, headache, and weakness, along with the characteristic buboes in the groin, armpit, or neck. If untreated, the infection can spread to the bloodstream or lungs, causing more severe illness. The disease mainly impacts the body's ability to fight infection and can be life-threatening without prompt medical care.
Clinical Definition
Bubonic plague is an acute zoonotic infection caused by the gram-negative bacillus Yersinia pestis. It is characterized by the rapid onset of fever, chills, and painful bubo formation due to lymphadenitis in regional lymph nodes. The disease is transmitted primarily through the bite of infected fleas that have fed on infected rodents, making it a vector-borne illness. The core pathology involves bacterial proliferation within lymph nodes, leading to intense inflammation and necrosis. If untreated, the infection can progress to septicemic or pneumonic plague, which have higher mortality rates. The disease is historically significant for causing large epidemics and remains a public health concern in endemic areas. Diagnosis and early treatment are critical to prevent systemic spread and fatal outcomes.
Inciting Event
Bite from an infected flea carrying Yersinia pestis is the primary inciting event.
Direct contact with infected animal tissues or fluids can also initiate infection.
Inhaled infectious droplets cause primary pneumonic plague. Lung seeding from bubonic/septicemic infection causes secondary pneumonic plague.
Latency Period
Bubonic plague usually develops 2-8 days after exposure; primary pneumonic disease has a shorter incubation, often 1-3 days.
Symptoms usually develop rapidly within the first week following exposure.
Diagnostic Delay
Nonspecific early symptoms such as fever and malaise can mimic common infections, delaying diagnosis.
Lack of awareness in non-endemic areas leads to missed or late consideration of plague.
Failure to recognize characteristic buboes or obtain appropriate cultures delays confirmation.
Limited access to specialized laboratory testing for Yersinia pestis identification.
Clinical Presentation
Signs & Symptoms
Sudden onset of high fever and chills
Painful, swollen lymph nodes (buboes) near flea bite or entry site
Headache and malaise
Fatigue and myalgias
Gastrointestinal symptoms such as nausea and vomiting in severe cases
History of Present Illness
Sudden onset of high fever and chills followed by severe malaise and headache.
Development of painful, swollen lymph nodes (buboes) near the flea bite site, commonly inguinal or axillary.
Associated symptoms include myalgia, nausea, and vomiting during systemic illness.
Progression to septicemia or secondary pneumonic plague may occur if untreated.
Past Medical History
Previous exposure to endemic environments or history of flea bites increases suspicion.
Record immune status and chronic disease to guide care, but their absence does not reduce the urgency of suspected plague.
Prior antibiotic use may mask or alter clinical presentation delaying diagnosis.
Family History
Plague is acquired, not inherited. Illness among household members suggests shared animal/flea exposure or close contact with pneumonic disease.
Physical Exam Findings
Tender, swollen lymph nodes (buboes) typically in the inguinal, axillary, or cervical regions
Fever and chills with associated diaphoresis
Tachycardia and hypotension in severe cases indicating systemic involvement
Petechiae or purpura may be present in septicemic plague
Signs of septic shock such as altered mental status and cold extremities
Diagnostic Workup
Diagnostic Criteria
Abrupt fever with an exquisitely tender regional bubo and relevant exposure warrants immediate suspicion. Alert public health and the laboratory; obtain blood and bubo specimens when feasible, but do not delay antibiotics for test results. Culture or reference-laboratory molecular testing establishes the organism; bipolar staining is only suggestive. Paired serology can provide later confirmation.
Pathophysiology
Key Mechanisms
Transmission via flea bite introduces Yersinia pestis into the skin, leading to local infection.
Bacterial proliferation in lymph nodes causes painful, swollen buboes characteristic of bubonic plague.
Early immune evasion allows bacterial expansion; later disseminated infection causes dysregulated inflammation, shock and DIC. Y. pestis LPS at mammalian temperature is a weak human TLR4 agonist, unlike a simple model of uniformly potent endotoxin activation.
Type III secretion of Yop effectors impairs phagocyte responses; the F1 capsule also contributes to antiphagocytic activity.
Microvascular thrombosis and necrosis contribute to tissue damage and gangrene in severe cases.
| Involvement | Details |
|---|---|
| Organs | Lymph nodes become enlarged and necrotic due to bacterial proliferation and immune response, producing the hallmark buboes. |
Spleen may become enlarged and involved in systemic infection and immune response. | |
Lungs can be affected in secondary pneumonic plague, leading to respiratory failure and transmission risk. | |
| Tissues | Lymphatic tissue is the primary site of Yersinia pestis replication, leading to characteristic swollen and painful buboes. |
Vascular endothelium is involved in bacterial dissemination and contributes to vascular leakage and hemorrhage. | |
| Cells | Macrophages phagocytose Yersinia pestis but the bacteria can survive intracellularly, facilitating dissemination. |
Neutrophils are recruited to infected lymph nodes and contribute to inflammation and abscess formation. | |
Dendritic cells present Yersinia pestis antigens to initiate adaptive immune responses. | |
| Chemical Mediators | Tumor necrosis factor-alpha (TNF-α) mediates systemic inflammation and fever in bubonic plague. |
Interleukin-1 beta (IL-1β) promotes local inflammation and recruitment of immune cells to infected tissues. | |
Mammalian-temperature hypoacylated lipid A weakly activates human TLR4, aiding early immune evasion. Severe late sepsis still produces systemic inflammatory injury. |
Treatments
Pharmacological Treatments
Streptomycin
- Mechanism:
Inhibits bacterial protein synthesis by binding the 30S ribosomal subunit of Yersinia pestis.
- Side effects:
Ototoxicity
Nephrotoxicity
Neuromuscular blockade
- Clinical role:
An effective first-line plague agent, but availability is limited in the US; gentamicin or a fluoroquinolone is commonly used. Treat promptly, generally for 10-14 days.
Gentamicin
- Mechanism:
Binds the 30S ribosomal subunit to inhibit protein synthesis in Yersinia pestis.
- Side effects:
Nephrotoxicity
Ototoxicity
Neuromuscular blockade
- Clinical role:
First-line treatment; monitor renal function and drug levels. Stable naturally acquired bubonic disease can receive one effective agent; severe/disseminated disease requires regimen reassessment.
Doxycycline
- Mechanism:
Inhibits bacterial protein synthesis by binding the 30S ribosomal subunit, effective against Yersinia pestis.
- Side effects:
Photosensitivity
Gastrointestinal upset
Tooth staining is a tetracycline-class concern, but short courses of doxycycline have not shown this effect and should not be withheld from children with plague.
- Clinical role:
First-line option for stable bubonic or pharyngeal plague, generally for 10-14 days; also used for indicated 7-day exposure prophylaxis. Severe pneumonic/septicemic disease has different preferred regimens.
Ciprofloxacin
- Mechanism:
Inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication in Yersinia pestis.
- Side effects:
Tendonitis
Gastrointestinal upset
QT prolongation
- Clinical role:
First-line fluoroquinolone option for plague treatment and exposure prophylaxis; route and regimen depend on severity and patient factors.
Non-pharmacological Treatments
Use standard precautions for bubonic disease; add droplet precautions for suspected or confirmed pneumonic plague until at least 48 hours of effective antibiotics and clinical improvement, or until excluded.
Supportive care including fluid resuscitation and oxygen therapy for systemic illness.
Antibiotics are essential. A suppurative bubo may require drainage after clinical assessment; drainage is not routine for every swollen node.
Prevention
Pharmacological Prevention
Give 7 days of post-exposure prophylaxis after qualifying close pneumonic contact or direct exposure to infected tissues/fluids, in consultation with public health.
Oral agents such as doxycycline, ciprofloxacin or levofloxacin are used for exposure prophylaxis; injectable aminoglycosides are not routine community prophylaxis.
Select prophylaxis by age, pregnancy and exposure; ciprofloxacin or levofloxacin are preferred options in pregnancy. Residence in an endemic region alone does not warrant antibiotics.
No widely available vaccine currently recommended for general use
Prompt antibiotic treatment of suspected cases to prevent spread
Non-pharmacological Prevention
Avoidance of flea bites through insect repellents and protective clothing
Reduce rodent habitat and protect pets from fleas; implement flea control before killing rodents, which otherwise may disperse infected fleas.
Use of personal protective equipment when handling potentially infected animals
Use pulmonary isolation and exposure-based contact assessment when indicated; blanket quarantine of all bubonic patients or contacts is not the routine approach.
Public health surveillance and education in endemic regions
Outcome & Complications
Complications
Septic shock with multiorgan failure
Disseminated intravascular coagulation (DIC) causing bleeding and thrombosis
Secondary pneumonic plague from hematogenous spread
Meningitis due to central nervous system invasion
Death if untreated or delayed treatment
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Bubonic Plague (Yersinia pestis) versus Tularemia
Bubonic Plague (Yersinia pestis) | Tularemia |
|---|---|
Contact with fleas from rodents or endemic areas | Contact with rabbits or ticks in rural areas |
Caused by Yersinia pestis | Caused by Francisella tularensis |
Positive culture or PCR for Yersinia pestis | Culture or paired seroconversion supports confirmation; early negative serology does not exclude tularemia. Notify the laboratory. |
Buboes are typically painful and swollen lymph nodes | Ulceroglandular disease causes an inoculation-site ulcer with regional lymphadenopathy; an ulcer is not always present. |
Bubonic Plague (Yersinia pestis) versus Cat Scratch Disease
Bubonic Plague (Yersinia pestis) | Cat Scratch Disease |
|---|---|
Flea/rodent exposure is typical, but sick cats can also transmit plague. | Often follows a cat scratch or bite; exposure alone does not distinguish it from plague. |
Caused by Yersinia pestis | Caused by Bartonella henselae |
Acute onset with high fever and rapid progression | Usually subacute regional lymphadenopathy with milder systemic symptoms; disseminated disease can be severe. |
Positive culture or PCR for Yersinia pestis | Compatible syndrome with supportive serology or specimen PCR; antibodies can cross-react or persist and PCR sensitivity varies. |
Bubonic Plague (Yersinia pestis) versus Lymphogranuloma Venereum
Bubonic Plague (Yersinia pestis) | Lymphogranuloma Venereum |
|---|---|
Exposure to flea bites or endemic rodent areas | Sexual contact with infected partner |
Caused by Yersinia pestis | Caused by Chlamydia trachomatis serovars L1-L3 |
Acute febrile illness with painful buboes | Transient genital lesion may disappear before painful inguinal buboes develop; rectal infection commonly causes proctocolitis. |
Positive culture or PCR for Yersinia pestis | CT NAAT at the symptomatic site supports presumptive LGV; LGV-specific genotyping distinguishes L1-L3 from other serovars. |
Bubonic Plague (Yersinia pestis) versus Staphylococcal or Streptococcal Lymphadenitis
Bubonic Plague (Yersinia pestis) | Staphylococcal or Streptococcal Lymphadenitis |
|---|---|
Caused by Yersinia pestis | Caused by Staphylococcus aureus or Streptococcus pyogenes |
Buboes with systemic symptoms and septicemia | Localized lymph node infection with abscess formation |
Small Gram-negative rods with suggestive bipolar staining; reference testing confirms the organism. | Gram-positive cocci on culture and microscopy |
Effective options include fluoroquinolones, aminoglycosides and, for stable bubonic disease, doxycycline. | Use pathogen- and susceptibility-directed treatment; ordinary beta-lactams do not reliably cover MRSA. |
Bubonic Plague (Yersinia pestis) versus Tularemic Pneumonia
Bubonic Plague (Yersinia pestis) | Tularemic Pneumonia |
|---|---|
Flea/animal exposure can lead to bubonic disease with secondary lung spread; inhalation causes primary pneumonic plague. | Inhalation of aerosolized Francisella tularensis |
Secondary pneumonia follows bloodstream spread; primary pneumonic plague follows inhalation. | Pneumonia can follow inhalation or secondary hematogenous spread from another form of tularemia. |
Caused by Yersinia pestis | Caused by Francisella tularensis |
Positive culture or PCR for Yersinia pestis | Positive culture or PCR for Francisella tularensis |